CO2023000516A2 - Composiciones de dosis orales unitarias compuestas de ibuprofeno y famotidina para el tratamiento de dolor agudo y la reducción de la gravedad yo riesgo de acidez estomacal referencia cruzada a solicitudes relacionadas - Google Patents
Composiciones de dosis orales unitarias compuestas de ibuprofeno y famotidina para el tratamiento de dolor agudo y la reducción de la gravedad yo riesgo de acidez estomacal referencia cruzada a solicitudes relacionadasInfo
- Publication number
- CO2023000516A2 CO2023000516A2 CONC2023/0000516A CO2023000516A CO2023000516A2 CO 2023000516 A2 CO2023000516 A2 CO 2023000516A2 CO 2023000516 A CO2023000516 A CO 2023000516A CO 2023000516 A2 CO2023000516 A2 CO 2023000516A2
- Authority
- CO
- Colombia
- Prior art keywords
- oral
- ibuprofen
- heartburn
- unit dose
- human
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 9
- 201000006549 dyspepsia Diseases 0.000 title abstract 4
- 208000024798 heartburn Diseases 0.000 title abstract 4
- 208000002193 Pain Diseases 0.000 title abstract 2
- 208000005298 acute pain Diseases 0.000 title abstract 2
- AULFVKUUIUIWQU-UHFFFAOYSA-N 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-n'-sulfamoylpropanimidamide;2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical group CC(C)CC1=CC=C(C(C)C(O)=O)C=C1.NC(N)=NC1=NC(CSCC\C(N)=N\S(N)(=O)=O)=CS1 AULFVKUUIUIWQU-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 3
- 229960001680 ibuprofen Drugs 0.000 abstract 3
- 238000004090 dissolution Methods 0.000 abstract 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 abstract 2
- 229960001596 famotidine Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen en el presente documento composiciones de dosis orales unitarias que reducen la gravedad de la acidez estomacal y/o el riesgo de la ocurrencia de la acidez estomacal en un humano en necesidad de tomar ibuprofeno para el tratamiento de OTC de dolor agudo en el que el humano no experimenta acidez estomacal antes de la administración oral de la composición de dosis oral unitaria que comprende administrar por vía oral al humano de una composición de dosis oral unitaria que comprende (i) ibuprofeno en una dosificación desde aproximadamente 50 mg hasta aproximadamente 400 mg por composición de dosis oral unitaria y (ii) famotidina en una dosificación desde aproximadamente 3 mg hasta aproximadamente 20 mg por composición de dosis oral unitaria, en la que la tasa de disolución de famotidina en la composición de dosis oral unitaria en dicho humano en un tiempo específico dentro de 45 minutos de administración de dicha composición de dosis oral unitaria a dicho humano es mayor que la tasa de disolución de ibuprofeno en la composición de dosis oral unitaria en dicho humano en el mismo tiempo especificado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063052398P | 2020-07-15 | 2020-07-15 | |
PCT/US2021/041521 WO2022015784A1 (en) | 2020-07-15 | 2021-07-14 | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023000516A2 true CO2023000516A2 (es) | 2023-01-26 |
Family
ID=77265221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0000516A CO2023000516A2 (es) | 2020-07-15 | 2023-01-17 | Composiciones de dosis orales unitarias compuestas de ibuprofeno y famotidina para el tratamiento de dolor agudo y la reducción de la gravedad yo riesgo de acidez estomacal referencia cruzada a solicitudes relacionadas |
Country Status (11)
Country | Link |
---|---|
US (2) | US11331307B2 (es) |
EP (1) | EP4181912A1 (es) |
JP (1) | JP2023534810A (es) |
KR (1) | KR20230051164A (es) |
CN (1) | CN116194102A (es) |
AU (1) | AU2021310264A1 (es) |
BR (1) | BR112023000598A2 (es) |
CA (1) | CA3159988C (es) |
CO (1) | CO2023000516A2 (es) |
IL (1) | IL299845A (es) |
WO (1) | WO2022015784A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL299845A (en) * | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn |
CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5102902A (en) | 1973-06-18 | 1992-04-07 | Mercer James B | Reagents and method for therapeutic treatment of multiple sclerosis |
US4279906A (en) | 1977-11-10 | 1981-07-21 | Nasa | Indomethacin-antihistamine combination for gastric ulceration control |
US4230717A (en) | 1978-12-29 | 1980-10-28 | Lovelace Alan M Administrator | Indomethacin-antihistamine combination for gastric ulceration control |
JPS6056143B2 (ja) | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
US4543370A (en) | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
JPS57209968A (en) | 1981-06-19 | 1982-12-23 | Kanegafuchi Chem Ind Co Ltd | Coated material having metallic finish |
US4599359A (en) | 1982-12-09 | 1986-07-08 | Stephen A. Cooper | Hydroxyzine-containing analgesic combinations |
US4794112A (en) | 1982-12-09 | 1988-12-27 | Cooper Stephen A | Acetaminophen/hydroxyzine analgesic combinations |
US4567183A (en) | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
US4683243A (en) | 1984-02-08 | 1987-07-28 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4755532A (en) | 1984-02-08 | 1988-07-05 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
US4783465A (en) | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4871733A (en) | 1984-04-09 | 1989-10-03 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
US5037815A (en) | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
HU196775B (en) | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
US4829064A (en) | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4975426A (en) | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US5009875A (en) | 1988-08-03 | 1991-04-23 | International Dioxcide, Inc. | Process of preparing clorine dioxide and apparatus therefor |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
IN171746B (es) | 1989-11-02 | 1992-12-26 | Mcneil Ppc Inc | |
US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
CA2092566A1 (en) | 1990-09-28 | 1992-03-29 | Thomas N. Gates | Ibuprofen-antihistamine combinations |
US5362737A (en) | 1991-04-09 | 1994-11-08 | Chemex Pharmaceuticals, Inc. | Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox |
EP0558876A1 (en) | 1992-03-03 | 1993-09-08 | STMicroelectronics S.r.l. | A semiconductor device package with shaped parts for direct coupling to standard connectors |
US5229137A (en) | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
US6303632B1 (en) | 1992-09-03 | 2001-10-16 | Sepracor Inc. | Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients |
CA2143610C (en) | 1992-09-03 | 2004-08-24 | Raymond L. Woosley | Use of norastemizole for the treatment of allergic disorders |
WO1994007541A1 (en) | 1992-09-29 | 1994-04-14 | Merck & Co., Inc. | Ibuprofen-h2 antagonist combinations |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
AU7973994A (en) | 1993-10-13 | 1995-05-04 | Merck & Co., Inc. | Combination therapy for hiv infection |
US5541212A (en) | 1994-01-10 | 1996-07-30 | Metatron, Inc. | Use of cimetidine for the control of retrovirus infections |
US5763422A (en) | 1995-01-27 | 1998-06-09 | Board Of Regents, The University Of Texas System | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
DE69534463T2 (de) | 1995-02-06 | 2006-06-14 | Alcatel Sa | Zellen-Vermittlungsnetz |
US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
US5955451A (en) | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
TW469135B (en) | 1995-10-03 | 2001-12-21 | Chugai Pharmaceutical Co Ltd | Chewable tablet |
DE69718358T2 (de) | 1996-02-15 | 2003-12-24 | Puratos N.V., Groot-Bijgaarden | Verfahren für die Herstellung eines verbesserten Strukturaufbaus von Backwaren |
GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
US6160020A (en) | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
US6027746A (en) | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
BRPI9802144B1 (pt) | 1997-05-30 | 2017-03-28 | Ezequiel Mayorga Jorge | dispositivo osmótico multicapa aperfeiçoado |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
US5993327A (en) | 1998-05-19 | 1999-11-30 | Terry Terril | Golf putting device and method of using the same to putt a golf ball |
US6071523A (en) | 1998-06-03 | 2000-06-06 | Taro Pharmaceuticals Industries, Ltd. | Spill resistant pharmaceutical compositions in semi-solid form |
GB2338896B (en) | 1998-07-02 | 2003-05-21 | Reckitt & Colmann Prod Ltd | Chewable Capsules |
US6270790B1 (en) | 1998-08-18 | 2001-08-07 | Mxneil-Ppc, Inc. | Soft, convex shaped chewable tablets having reduced friability |
ATE232382T1 (de) | 1998-09-10 | 2003-02-15 | Nycomed Danmark As | Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen |
US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
EP1140066A4 (en) | 1998-11-17 | 2005-11-09 | Nitromed Inc | NITRO- AND NITROSYL COMPOUNDS OF H2 RECEPTOR ANTAGONISTS, COMPOSITIONS AND THEIR USES OF USE |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
GB9910212D0 (en) | 1999-05-05 | 1999-06-30 | Reckitt & Colmann Prod Ltd | Improvements in or relating to organic compositions |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
US6432415B1 (en) | 1999-12-17 | 2002-08-13 | Axrix Laboratories, Inc. | Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces |
DK1276470T3 (da) | 2000-04-20 | 2007-06-18 | Novartis Ag | Smagskaskerende overtrækssammensætning |
US7678387B2 (en) | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
US6375982B1 (en) | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
US6417184B1 (en) | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
EA006398B1 (ru) | 2001-06-01 | 2005-12-29 | Поузен Инк. | Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств |
EP1438018B1 (en) | 2001-09-28 | 2010-08-11 | McNeil-PPC, Inc. | Fondant-based pharmaceutical composition |
US6767200B2 (en) | 2001-09-28 | 2004-07-27 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US6827946B2 (en) | 2001-12-05 | 2004-12-07 | Collegium Pharmaceutical, Inc. | Compositions containing both sedative and non-sedative antihistamines |
EP1471872A2 (en) | 2002-02-04 | 2004-11-03 | Pharmacia Corporation | Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof |
EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
EP1494671B1 (en) | 2002-04-18 | 2011-10-19 | Schering Corporation | 1-(4-piperidinyl)benzimidazolones as histamine h3 antagonists |
US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
MY135686A (en) | 2002-06-24 | 2008-06-30 | Schering Corp | Indole derivatives useful as histamine h3 antagonists |
CA2524806C (en) | 2003-05-07 | 2011-07-12 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
EP1677755A4 (en) | 2003-10-28 | 2011-12-28 | Taro Pharmaceuticals Usa Inc | FORMULATIONS BASED ON RINGS AT THE D BORDEMENT |
US20060034943A1 (en) | 2003-10-31 | 2006-02-16 | Technology Innovations Llc | Process for treating a biological organism |
US20050095197A1 (en) | 2003-10-31 | 2005-05-05 | Tuszynski Jack A. | Anti-mitotic compound |
US20050266032A1 (en) | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
WO2005063219A2 (en) | 2003-12-23 | 2005-07-14 | Ranbaxy Laboratories Limited | Ibuprofen-containing soft gelatin capsules |
US20050163847A1 (en) | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
WO2006052856A1 (en) | 2004-11-04 | 2006-05-18 | Reliant Pharmaceuticals, Inc. | System and method of treatment with nizatidine |
US20080020040A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
CN101257800B (zh) | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | 包含法莫替丁和布洛芬的药物 |
US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
US20080085314A1 (en) | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
WO2007054480A1 (en) | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
US20070154542A1 (en) | 2005-12-30 | 2007-07-05 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
JP2009526755A (ja) | 2006-01-10 | 2009-07-23 | ユー, リュイ ジェイ. | N−(ホスホノアルキル)−アミノ酸、その誘導体及び組成物及びその利用法 |
US20070202058A1 (en) * | 2006-02-27 | 2007-08-30 | Calwood Nutritionals, Inc. | Compositions for treating gastric reflux |
PE20080188A1 (es) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
US8067033B2 (en) * | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
BRPI0714937A2 (pt) | 2006-07-18 | 2013-03-26 | Horizon Therapeutics Inc | forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria |
EP2063873A2 (en) | 2006-08-31 | 2009-06-03 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
WO2008070268A2 (en) | 2006-10-09 | 2008-06-12 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
CA2930063C (en) | 2008-01-04 | 2017-01-31 | Schabar Research Associates Llc | Unit oral solid dose compositions composed of naproxen sodium and nizatidine |
IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
US20090233970A1 (en) | 2008-03-11 | 2009-09-17 | Nickell Robert P | Combined nsaid and acid blocker formulation and method |
US20090275622A1 (en) | 2008-04-30 | 2009-11-05 | Prasoona Linga | Nizatidine formulations |
CN109999013A (zh) | 2012-02-29 | 2019-07-12 | 普马特里克斯营业公司 | 可吸入干粉剂 |
WO2019180038A1 (en) | 2018-03-20 | 2019-09-26 | Dsm Ip Assets B.V. | Topical composition |
CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
IL299845A (en) * | 2020-07-15 | 2023-03-01 | Schabar Res Associates Llc | Oral unit dose compounds consisting of ibuprofen and famotidine for the treatment of acute pain and to reduce the severity and/or risk of heartburn |
-
2021
- 2021-07-14 IL IL299845A patent/IL299845A/en unknown
- 2021-07-14 JP JP2023503095A patent/JP2023534810A/ja active Pending
- 2021-07-14 AU AU2021310264A patent/AU2021310264A1/en active Pending
- 2021-07-14 KR KR1020237002480A patent/KR20230051164A/ko unknown
- 2021-07-14 EP EP21752328.1A patent/EP4181912A1/en active Pending
- 2021-07-14 BR BR112023000598A patent/BR112023000598A2/pt unknown
- 2021-07-14 CN CN202180060591.XA patent/CN116194102A/zh active Pending
- 2021-07-14 WO PCT/US2021/041521 patent/WO2022015784A1/en active Search and Examination
- 2021-07-14 US US17/375,049 patent/US11331307B2/en active Active
- 2021-07-14 CA CA3159988A patent/CA3159988C/en active Active
-
2022
- 2022-04-12 US US17/658,852 patent/US20220233510A1/en active Pending
-
2023
- 2023-01-17 CO CONC2023/0000516A patent/CO2023000516A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3159988C (en) | 2023-09-19 |
CA3159988A1 (en) | 2022-01-20 |
US11331307B2 (en) | 2022-05-17 |
WO2022015784A1 (en) | 2022-01-20 |
IL299845A (en) | 2023-03-01 |
BR112023000598A2 (pt) | 2023-01-31 |
AU2021310264A1 (en) | 2023-02-09 |
KR20230051164A (ko) | 2023-04-17 |
CN116194102A (zh) | 2023-05-30 |
JP2023534810A (ja) | 2023-08-14 |
EP4181912A1 (en) | 2023-05-24 |
US20220016088A1 (en) | 2022-01-20 |
US20220233510A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000516A2 (es) | Composiciones de dosis orales unitarias compuestas de ibuprofeno y famotidina para el tratamiento de dolor agudo y la reducción de la gravedad yo riesgo de acidez estomacal referencia cruzada a solicitudes relacionadas | |
Kawashita et al. | Oral management strategies for radiotherapy of head and neck cancer | |
da Cruz Campos et al. | Oral mucositis in cancer treatment: Natural history, prevention and treatment | |
Drisko | Nonsurgical periodontal therapy. | |
RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
ES2254046T1 (es) | Tratamiento de hiperplasia prostatica benigna. | |
Sharma et al. | Severe tissue necrosis following intra-arterial injection of endodontic calcium hydroxide: a case series | |
Yavari et al. | The effect of submucosal injection of corticosteroids on pain perception and quality of life after root canal treatment of teeth with irreversible pulpitis: a randomized clinical trial | |
Alamassi | Endodontic postoperative pain: etiology and related factors–an update | |
Kumar et al. | Evaluating combined effect of oral premedication with ibuprofen and dexamethasone on success of inferior alveolar nerve block in mandibular molars with symptomatic irreversible pulpitis: a prospective, double-blind, randomized clinical trial | |
Vargo et al. | Garlic burn of the oral mucosa: a case report and review of self-treatment chemical burns | |
da Silva Sampieri et al. | Central giant cell granuloma: treatment with calcitonin, triamcinolone acetonide, and a cystic finding 3 years and 6 months after the primary treatment | |
Olsen et al. | Nerve lesions following apical extrusion of non-setting calcium hydroxide: a systematic case review and report of two cases | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
Kawashita et al. | Prophylactic bundle for radiation-induced oral mucositis in oral or oropharyngeal cancer patients | |
Dabarakis et al. | Needle-less local anesthesia: clinical evaluation of the effectiveness of the jet anesthesia Injex in local anesthesia in dentistry. | |
Amaliya et al. | The effectiveness of 0.2% chlorhexidine gel on early wound healing after tooth extraction: a randomized controlled trial | |
JPH0796486B2 (ja) | 歯科用抗炎症剤組成物 | |
Timoshin et al. | Experience in the use of collagen phytoplates in the treatment of gingivitis | |
AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
Venkatasatya et al. | Phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw | |
WO2021060962A1 (ru) | Лечебно-профилактическая композиция для стоматологии | |
Shemer et al. | Efficacy of a mucoadhesive patch compared with an oral solution for treatment of aphthous stomatitis | |
Prasad et al. | Comparison of calcium hydroxide and triple antibiotic paste as intracanal medicament in emergency pain reduction: in vivo study | |
Arslan et al. | Effect of calcium hydroxide mixed with lidocaine hydrochloride on postoperative pain in teeth with irreversible pulpitis and symptomatic apical periodontitis: a preliminary randomized controlled prospective clinical trial |